Alan F. Denenberg
Lawyers
Filters
McKesson $850 million acquisition of controlling interest in PRISM Vision
We are advising McKesson on the transaction
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Personalis $50 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Nutanix $862.5 million convertible senior notes offering
The 0.5% convertible senior notes are due 2029
MARA Holdings $850 million convertible notes offering
The convertible notes are due 2031
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
indie Semiconductor $218.5 million convertible senior notes offering
The 3.5% convertible senior notes are due 2029
Fastly $150 million convertible senior notes offering
The 7.75% convertible notes are due 2028
ACELYRIN $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market